BioWorld International Correspondent
LONDON u GenKyoTex SA raised CHF18 million (US$20.4 million) in a Series C round, enabling it to take the lead product to the point where it is ready to deliver proof of concept for the company's NOX enzyme inhibition technology.
At the same time, it was announced that Ursula Ney, former chief operating officer of the UK biotech firm Antisoma plc, has been installed as CEO of Geneva-based GenKyoTex. Her appointment was a condition of the new investors in the round, led by Edmond de Rothschild Partners and including Vesalius Biocapital Partners and MP Healthcare Venture Management.
The existing backers, the business incubator Eclosion, …
No comments:
Post a Comment